Late cardiac effects of cancer treatment
- PMID: 23008297
- DOI: 10.1200/JCO.2012.45.2938
Late cardiac effects of cancer treatment
Erratum in
- J Clin Oncol. 2012 Dec 20;30(36):4590
Abstract
Cardiac toxicities from cancer therapy can become evident many years after treatment, and these late cardiac effects can have a profound impact on cancer survivors. There are a myriad of potential cardiovascular complications from cancer therapy, but these can be grouped into three main categories. First, vascular conditions including atherosclerosis, thrombosis, and hypertension predominate. Second, cardiac structural problems, especially valvular degeneration, can have a dramatic impact long term. Lastly, and most importantly, cardiac dysfunction and heart failure are potentially common late cardiac effects and can certainly be prevented or detected early during active cancer therapy to result in optimal outcomes. Future research on late cardiac effects in cancer survivors needs to include advanced cardiac imaging techniques, novel cardiac biomarkers, and genetic determinants of response to cancer treatment.
Comment in
-
Dexrazoxane prevention of anthracycline cardiomyopathy.J Clin Oncol. 2013 Apr 1;31(10):1379. doi: 10.1200/JCO.2012.46.9908. Epub 2013 Feb 25. J Clin Oncol. 2013. PMID: 23439750 No abstract available.
-
Reply to R. Steiner et al.J Clin Oncol. 2013 Apr 1;31(10):1380. doi: 10.1200/JCO.2012.48.1788. J Clin Oncol. 2013. PMID: 23662307 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical